| Authors: |
Vandyck K; Aligos Belgium BV, Gaston Geenslaan 1, 3001 Leuven, Belgium. Electronic address: kvandyck@aligos.com., Abdelnabi R; Rega Institute for Medical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium., Gupta K; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA., Jochmans D; Rega Institute for Medical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium., Jekle A; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA., Deval J; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA., Misner D; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA., Bardiot D; CISTIM Leuven vzw, Gaston Geenslaan 2, 3001 Leuven, Belgium., Foo CS; Rega Institute for Medical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium., Liu C; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA., Ren S; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA., Beigelman L; Aligos Belgium BV, Gaston Geenslaan 1, 3001 Leuven, Belgium; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA., Blatt LM; Aligos Belgium BV, Gaston Geenslaan 1, 3001 Leuven, Belgium; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA., Boland S; CISTIM Leuven vzw, Gaston Geenslaan 2, 3001 Leuven, Belgium., Vangeel L; Rega Institute for Medical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium., Dejonghe S; Rega Institute for Medical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium., Chaltin P; Centre for Drug Design and Discovery (CD3), KU Leuven, Gaston Geenslaan 2, 3001 Leuven, Belgium; CISTIM Leuven vzw, Gaston Geenslaan 2, 3001 Leuven, Belgium., Marchand A; CISTIM Leuven vzw, Gaston Geenslaan 2, 3001 Leuven, Belgium., Serebryany V; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA., Stoycheva A; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA., Chanda S; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA., Symons JA; Aligos Therapeutics, Inc., 1 Corporate Dr., 2nd Floor, South San Francisco, CA, USA., Raboisson P; Aligos Belgium BV, Gaston Geenslaan 1, 3001 Leuven, Belgium., Neyts J; Rega Institute for Medical Research, KU Leuven, Herestraat 49, 3000 Leuven, Belgium. Electronic address: johan.neyts@kuleuven.be. |
